EVALUATION OF THE EFFICACY, SAFETY, AND TOLERABILITY OF ORALLY ADMINISTERED BI 409306, A NOVEL PHOSPHODIESTERASE 9 INHIBITOR, IN TWO RANDOMIZED CONTROLLED PHASE II STUDIES IN PATIENTS WITH PRODROMAL AND MILD ALZHEIMER’S DISEASE

Lutz Fr?lich; Glen Wunderlich; Claus Thamer; Michael Roehrle; Miguel Garcia; Bruno Dubois

首页> 外文期刊>Alzheimer’s & dementia: the journal of the Alzheimer’s Association >EVALUATION OF THE EFFICACY, SAFETY, AND TOLERABILITY OF ORALLY ADMINISTERED BI 409306, A NOVEL PHOSPHODIESTERASE 9 INHIBITOR, IN TWO RANDOMIZED CONTROLLED PHASE II STUDIES IN PATIENTS WITH PRODROMAL AND MILD ALZHEIMER’S DISEASE

【24h】

EVALUATION OF THE EFFICACY, SAFETY, AND TOLERABILITY OF ORALLY ADMINISTERED BI 409306, A NOVEL PHOSPHODIESTERASE 9 INHIBITOR, IN TWO RANDOMIZED CONTROLLED PHASE II STUDIES IN PATIENTS WITH PRODROMAL AND MILD ALZHEIMER’S DISEASE

机译：评估口服给药BI 409306，一种新型磷酸二酯酶9抑制剂的疗效，安全性和耐受性，在前一种随机对照期II研究中的前一种患者和轻度阿尔茨海默病患者疾病

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

著录项
相似文献
相关主题

著录项

来源
《Alzheimer’s & dementia: the journal of the Alzheimer’s Association》 |2018年第7期|共2页
作者
Lutz Fr?lich; Glen Wunderlich; Claus Thamer; Michael Roehrle; Miguel Garcia; Bruno Dubois;
展开▼
作者单位

Department of Geriatric Psychiatry Central Institute of Mental Health Medical Faculty Mannheim;

Boehringer Ingelheim (Canada) Ltd;

Boehringer Ingelheim Pharma GmbH &

Co. KG;

Boehringer Ingelheim Pharma GmbH &

Co. KG;

Boehringer Ingelheim Pharmaceuticals Inc;

Institut de la Mémoire et de la Maladie d'Alzheimer (IM2A) Département de Neurologie H?pital de;

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类神经病学与精神病学;
关键词

相似文献

外文文献
中文文献
专利

1. EVALUATION OF THE EFFICACY, SAFETY, AND TOLERABILITY OF ORALLY ADMINISTERED BI 409306, A NOVEL PHOSPHODIESTERASE 9 INHIBITOR, IN TWO RANDOMIZED CONTROLLED PHASE II STUDIES IN PATIENTS WITH PRODROMAL AND MILD ALZHEIMER’S DISEASE [J] . Lutz Fr?lich, Glen Wunderlich, Claus Thamer, Alzheimer’s & dementia: the journal of the Alzheimer’s Association . 2018,第7期

机译：评估口服给药BI 409306，一种新型磷酸二酯酶9抑制剂的疗效，安全性和耐受性，在前一种随机对照期II研究中的前一种患者和轻度阿尔茨海默病患者疾病
2. Evaluation of the Efficacy, Safety, and Tolerability of BI 409306, a Novel Phosphodiesterase 9 Inhibitor, in Cognitive Impairment in Schizophrenia: A Randomized, Double-Blind, Placebo-Controlled, Phase II Trial [J] . Brown David, Nakagome Kazuyuki, Cordes Joachim, Schizophrenia bulletin . 2019,第2期

机译：评估BI 409306，一种新型磷酸二酯酶9抑制剂的疗效，安全性和可耐药性，在精神分裂症中的认知障碍：随机，双盲，安慰剂控制，II期试验
3. Rationale and study design of a randomized, placebo-controlled, double-blind phase 2b trial to evaluate efficacy, safety, and tolerability of an oral glutaminyl cyclase inhibitor varoglutamstat (PQ912) in study participants with MCI and mild AD—VIVIAD [J] . Vijverberg E. G. B., Axelsen T. M., Bihlet A. R., Alzheimer s Research & Therapy . 2021,第1期

机译：随机，安慰剂，双盲相2B试验的理由和研究设计，以评估口服谷氨酸环酰基环化酶抑制剂Varoglutamstat（PQ912）的疗效，安全性和可耐受性与MCI和轻度AD-VIVIAD的研究参与者
4. A Randomized, Placebo-Controlled Study of the Efficacy of Cognitive Intervention on Elderly People and on Patient's with Alzheimer's Disease [C] . J.J. Yanguas, C. Buiza, I. Etxeberria, International Conference on Computers Helping People with Special Needs(ICCHP 2006); 20060711-13; Linz(AT) . 2006

机译：认知干预对老年人和阿尔茨海默氏病患者疗效的随机，安慰剂对照研究
5. Safety and Efficacy of the Immunomodulatory Drug (IMiD) Lenalidomide in Patients with Lymphoma: Development of RU051417I - Phase I/II Open-Label Study of R-ICE (Rituximab-Ifosfamide-Carboplatin-Etoposide) with Lenalidomide [R2-ICE] in Patients with First-Relapse/Primary Refractory Diffuse Large B-Cell Lymphoma (DLBCL). [D] . Kasi, Pashtoon Murtaza. 2018

机译：免疫调节药物来那度胺在淋巴瘤患者中的安全性和有效性：RU051417I-R-ICE（利妥昔单抗-异环磷酰胺-卡铂-依托泊苷）与来那度胺[R2-ICE]的I / II期开放标签研究的进展初次复发/原发性难治性弥漫性大B细胞淋巴瘤（DLBCL）。
6. Evaluation of the efficacy safety and tolerability of orally administered BI 409306 a novel phosphodiesterase type 9 inhibitor in two randomised controlled phase II studies in patients with prodromal and mild Alzheimer’s disease [O] . Lutz Frölich, Glen Wunderlich, Claus Thamer, 2019

机译：在两项前驱性和轻度阿尔茨海默氏病患者的随机II期随机对照研究中评估了口服给药的新型9型磷酸二酯酶BI 409306的疗效安全性和耐受性
7. Evaluation of the efficacy, safety and tolerability of orally administered BI 409306, a novel phosphodiesterase type 9 inhibitor, in two randomised controlled phase II studies in patients with prodromal and mild Alzheimer’s disease [O] . Lutz Frölich, Glen Wunderlich, Claus Thamer, 2019

机译：评估口服给药BI 409306的疗效，安全性和耐受性，一种新型磷酸二酯酶9抑制剂，在患有前一种随机的对照期II研究中，患者的前驱和轻度阿尔茨海默病患者疾病

EVALUATION OF THE EFFICACY, SAFETY, AND TOLERABILITY OF ORALLY ADMINISTERED BI 409306, A NOVEL PHOSPHODIESTERASE 9 INHIBITOR, IN TWO RANDOMIZED CONTROLLED PHASE II STUDIES IN PATIENTS WITH PRODROMAL AND MILD ALZHEIMER’S DISEASE

著录项

相似文献

相关主题

期刊订阅